Moderna plans to submit an application to the US health regulator for emergency use authorization (EUA) of its Covid-19 vaccine among kids between the ages of six months to five years by end of the month. The Omicron variant was predominant during Moderna's pediatric trial, and the drugmaker said two doses were around 38% effective in preventing infections in 2 to 5-year-olds and 44% effective for children aged 6 months to under 2 years.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/iLs36GK
via gqrds
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment